Patients in the anakinra group achieed an A1C leel -- an indicator of long term glucose control -- that was 46 percent lower than that of patients gien the placebo.

• 用药组患者血糖水平评价为A1C，即长期血糖控制水平，较安慰剂对照组低46%25。